vs

Side-by-side financial comparison of Arcosa, Inc. (ACA) and Natera, Inc. (NTRA). Click either name above to swap in a different company.

Arcosa, Inc. is the larger business by last-quarter revenue ($716.7M vs $665.5M, roughly 1.1× Natera, Inc.). Arcosa, Inc. runs the higher net margin — 7.3% vs 7.1%, a 0.2% gap on every dollar of revenue. On growth, Natera, Inc. posted the faster year-over-year revenue change (39.8% vs 7.6%). Arcosa, Inc. produced more free cash flow last quarter ($55.8M vs $37.8M). Over the past eight quarters, Natera, Inc.'s revenue compounded faster (34.5% CAGR vs 9.4%).

Arcosa, Inc. is a provider of infrastructure-related products and solutions operating across three core segments: construction, energy, and transportation. It offers products including utility structures, construction aggregates, and transportation components, primarily serving customers across the North American market to support critical infrastructure development projects.

Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendment...

ACA vs NTRA — Head-to-Head

Bigger by revenue
ACA
ACA
1.1× larger
ACA
$716.7M
$665.5M
NTRA
Growing faster (revenue YoY)
NTRA
NTRA
+32.2% gap
NTRA
39.8%
7.6%
ACA
Higher net margin
ACA
ACA
0.2% more per $
ACA
7.3%
7.1%
NTRA
More free cash flow
ACA
ACA
$18.0M more FCF
ACA
$55.8M
$37.8M
NTRA
Faster 2-yr revenue CAGR
NTRA
NTRA
Annualised
NTRA
34.5%
9.4%
ACA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACA
ACA
NTRA
NTRA
Revenue
$716.7M
$665.5M
Net Profit
$52.1M
$47.3M
Gross Margin
22.9%
Operating Margin
11.0%
-3.4%
Net Margin
7.3%
7.1%
Revenue YoY
7.6%
39.8%
Net Profit YoY
776.6%
187.9%
EPS (diluted)
$1.06
$0.36

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACA
ACA
NTRA
NTRA
Q4 25
$716.7M
$665.5M
Q3 25
$797.8M
$592.2M
Q2 25
$736.9M
$546.6M
Q1 25
$632.0M
$501.8M
Q4 24
$666.2M
$476.1M
Q3 24
$640.4M
$439.8M
Q2 24
$664.7M
$413.4M
Q1 24
$598.6M
$367.7M
Net Profit
ACA
ACA
NTRA
NTRA
Q4 25
$52.1M
$47.3M
Q3 25
$73.0M
$-87.5M
Q2 25
$59.7M
$-100.9M
Q1 25
$23.6M
$-66.9M
Q4 24
$-7.7M
$-53.8M
Q3 24
$16.6M
$-31.6M
Q2 24
$45.6M
$-37.5M
Q1 24
$39.2M
$-67.6M
Gross Margin
ACA
ACA
NTRA
NTRA
Q4 25
22.9%
Q3 25
24.1%
Q2 25
22.5%
Q1 25
19.8%
Q4 24
19.3%
Q3 24
21.3%
Q2 24
20.8%
Q1 24
18.6%
Operating Margin
ACA
ACA
NTRA
NTRA
Q4 25
11.0%
-3.4%
Q3 25
14.1%
-16.5%
Q2 25
12.9%
-20.2%
Q1 25
8.8%
-15.8%
Q4 24
6.5%
-13.6%
Q3 24
5.3%
-8.9%
Q2 24
10.1%
-10.6%
Q1 24
8.9%
-20.2%
Net Margin
ACA
ACA
NTRA
NTRA
Q4 25
7.3%
7.1%
Q3 25
9.2%
-14.8%
Q2 25
8.1%
-18.5%
Q1 25
3.7%
-13.3%
Q4 24
-1.2%
-11.3%
Q3 24
2.6%
-7.2%
Q2 24
6.9%
-9.1%
Q1 24
6.5%
-18.4%
EPS (diluted)
ACA
ACA
NTRA
NTRA
Q4 25
$1.06
$0.36
Q3 25
$1.48
$-0.64
Q2 25
$1.22
$-0.74
Q1 25
$0.48
$-0.50
Q4 24
$-0.16
$-0.41
Q3 24
$0.34
$-0.26
Q2 24
$0.93
$-0.30
Q1 24
$0.80
$-0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACA
ACA
NTRA
NTRA
Cash + ST InvestmentsLiquidity on hand
$214.6M
Total DebtLower is stronger
$1.5B
Stockholders' EquityBook value
$2.6B
$1.7B
Total Assets
$5.0B
$2.4B
Debt / EquityLower = less leverage
0.57×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACA
ACA
NTRA
NTRA
Q4 25
$214.6M
Q3 25
$220.0M
$1.0M
Q2 25
$189.7M
$16.0M
Q1 25
$167.9M
$17.8M
Q4 24
$187.3M
$22.7M
Q3 24
$756.8M
$29.5M
Q2 24
$103.7M
$90.3M
Q1 24
$176.5M
$69.1M
Total Debt
ACA
ACA
NTRA
NTRA
Q4 25
$1.5B
Q3 25
$1.6B
Q2 25
$1.7B
Q1 25
$1.7B
Q4 24
$1.7B
Q3 24
$1.2B
Q2 24
$699.9M
Q1 24
$600.6M
Stockholders' Equity
ACA
ACA
NTRA
NTRA
Q4 25
$2.6B
$1.7B
Q3 25
$2.6B
$1.3B
Q2 25
$2.5B
$1.2B
Q1 25
$2.5B
$1.2B
Q4 24
$2.4B
$1.2B
Q3 24
$2.4B
$878.5M
Q2 24
$2.4B
$836.5M
Q1 24
$2.4B
$794.1M
Total Assets
ACA
ACA
NTRA
NTRA
Q4 25
$5.0B
$2.4B
Q3 25
$5.1B
$1.8B
Q2 25
$5.0B
$1.8B
Q1 25
$4.9B
$1.7B
Q4 24
$4.9B
$1.7B
Q3 24
$4.4B
$1.6B
Q2 24
$3.8B
$1.5B
Q1 24
$3.7B
$1.5B
Debt / Equity
ACA
ACA
NTRA
NTRA
Q4 25
0.57×
Q3 25
0.61×
Q2 25
0.67×
Q1 25
0.68×
Q4 24
0.69×
Q3 24
0.51×
Q2 24
0.29×
Q1 24
0.25×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACA
ACA
NTRA
NTRA
Operating Cash FlowLast quarter
$120.0M
$73.9M
Free Cash FlowOCF − Capex
$55.8M
$37.8M
FCF MarginFCF / Revenue
7.8%
5.7%
Capex IntensityCapex / Revenue
9.0%
5.4%
Cash ConversionOCF / Net Profit
2.30×
1.56×
TTM Free Cash FlowTrailing 4 quarters
$175.5M
$109.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACA
ACA
NTRA
NTRA
Q4 25
$120.0M
$73.9M
Q3 25
$160.6M
$59.4M
Q2 25
$61.2M
$37.6M
Q1 25
$-700.0K
$44.5M
Q4 24
$248.2M
$52.9M
Q3 24
$135.0M
$51.8M
Q2 24
$38.3M
$4.0M
Q1 24
$80.5M
$27.0M
Free Cash Flow
ACA
ACA
NTRA
NTRA
Q4 25
$55.8M
$37.8M
Q3 25
$121.0M
$37.0M
Q2 25
$33.4M
$11.7M
Q1 25
$-34.7M
$22.6M
Q4 24
$194.9M
$34.8M
Q3 24
$100.6M
$35.5M
Q2 24
$-9.3M
$-7.7M
Q1 24
$26.1M
$6.7M
FCF Margin
ACA
ACA
NTRA
NTRA
Q4 25
7.8%
5.7%
Q3 25
15.2%
6.2%
Q2 25
4.5%
2.1%
Q1 25
-5.5%
4.5%
Q4 24
29.3%
7.3%
Q3 24
15.7%
8.1%
Q2 24
-1.4%
-1.9%
Q1 24
4.4%
1.8%
Capex Intensity
ACA
ACA
NTRA
NTRA
Q4 25
9.0%
5.4%
Q3 25
5.0%
3.8%
Q2 25
3.8%
4.7%
Q1 25
5.4%
4.3%
Q4 24
8.0%
3.8%
Q3 24
5.4%
3.7%
Q2 24
7.2%
2.8%
Q1 24
9.1%
5.5%
Cash Conversion
ACA
ACA
NTRA
NTRA
Q4 25
2.30×
1.56×
Q3 25
2.20×
Q2 25
1.03×
Q1 25
-0.03×
Q4 24
Q3 24
8.13×
Q2 24
0.84×
Q1 24
2.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACA
ACA

Engineered Structures$301.1M42%
Total Construction Materials$276.8M39%
Specialty Materials And Asphalt$110.2M15%
Construction Site Support$28.6M4%

NTRA
NTRA

Segment breakdown not available.

Related Comparisons